These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 35693049)
1. A case of ceftriaxone-induced liver injury and literature review. Guarino M; Perna B; Pastorelli A; Bertolazzi P; Caio G; Maritati M; De Giorgio R; Contini C Infez Med; 2022; 30(2):293-297. PubMed ID: 35693049 [TBL] [Abstract][Full Text] [Related]
3. Ceftriaxone-induced hepatotoxicity in patients with common medical infections in Qatar: A retrospective study. Barman M; Al Hariri B; Rahman Mustafa A; Ambra N; Amjed I; Eid Nazzal Alharafsheh A; Illahi MN; Hamuda S; Gaafar M; Sharif M Qatar Med J; 2022; 2022(3):27. PubMed ID: 35864919 [TBL] [Abstract][Full Text] [Related]
4. Ceftriaxone-induced cholestatic hepatitis in a child: A case report and a review of the literature. Castellazzi ML; Agostoni CV; Palella J; Civeriati D; Marchisio P; Nebbia G Front Pediatr; 2022; 10():1051887. PubMed ID: 36545656 [TBL] [Abstract][Full Text] [Related]
6. An Update on Drug-induced Liver Injury. Devarbhavi H J Clin Exp Hepatol; 2012 Sep; 2(3):247-59. PubMed ID: 25755441 [TBL] [Abstract][Full Text] [Related]
7. In vitro activity, pharmacokinetics, clinical efficacy, safety and pharmacoeconomics of ceftriaxone compared with third and fourth generation cephalosporins: review. Bijie H; Kulpradist S; Manalaysay M; Soebandrio A J Chemother; 2005 Feb; 17(1):3-24. PubMed ID: 15828439 [TBL] [Abstract][Full Text] [Related]
13. Severe tyrosine-kinase inhibitor induced liver injury in metastatic renal cell carcinoma patients: two case reports assessed for causality using the updated RUCAM and review of the literature. Studentova H; Volakova J; Spisarova M; Zemankova A; Aiglova K; Szotkowski T; Melichar B BMC Gastroenterol; 2022 Feb; 22(1):49. PubMed ID: 35123392 [TBL] [Abstract][Full Text] [Related]
14. Carvedilol-Induced Liver Injury, a Rare Cause of Mixed Hepatitis: A Clinical Case. Rua J; Prata AR; Marques R; Silva R; Gomes B; Fraga J; Fortuna J GE Port J Gastroenterol; 2019 May; 26(3):196-201. PubMed ID: 31192288 [TBL] [Abstract][Full Text] [Related]
15. Azithromycin-Induced Liver Injury in Legionnaires' Disease. Wong KM; Hosseinnejad K; Palaparty P; Ravakhah K Cureus; 2021 Sep; 13(9):e17856. PubMed ID: 34660061 [TBL] [Abstract][Full Text] [Related]
16. Ceftriaxone-induced hemolytic anemia and hepatitis in an adolescent with hemoglobin SC disease. Bell MJ; Stockwell DC; Luban NL; Shirey RS; Shaak L; Ness PM; Wong EC Pediatr Crit Care Med; 2005 May; 6(3):363-6. PubMed ID: 15857541 [TBL] [Abstract][Full Text] [Related]
17. Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections. Lamb HM; Ormrod D; Scott LJ; Figgitt DP Drugs; 2002; 62(7):1041-89. PubMed ID: 11985490 [TBL] [Abstract][Full Text] [Related]
18. Implications of current recommendations for third-generation cephalosporin use in the WHO Western Pacific Region following the emergence of multiresistant gonococci. Tapsall JW Sex Transm Infect; 2009 Aug; 85(4):256-8. PubMed ID: 19261600 [TBL] [Abstract][Full Text] [Related]
19. Lenalidomide-associated hepatotoxicity--a case report and literature review. Nojkov B; Signori C; Konda A; Fontana RJ Anticancer Res; 2012 Sep; 32(9):4117-9. PubMed ID: 22993370 [TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacokinetics of the third generation cephalosporins. Balant L; Dayer P; Auckenthaler R Clin Pharmacokinet; 1985; 10(2):101-43. PubMed ID: 3888488 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]